呼吸道合胞病毒是引起兒童下呼吸道感染的主要原因,目前臨床主要的治療措施為對癥支持治療,尚缺乏特異性抗病毒藥物和安全有效的預(yù)防措施。近年來,多種新型藥物已經(jīng)進入了臨床研究后階段,部分藥物已上市。綜述了治療呼吸道合胞病毒的早期和新型抗病毒藥物的研究進展以及呼吸道合胞病毒主動、被動免疫預(yù)防策略,旨在提高臨床醫(yī)生對兒童呼吸道合胞病毒防治策略的認識。

Respiratory syncytial virus (RSV) is the main cause of lower respiratory tract infection in infants. At present, the main clinical treatment measures for RSV were symptomatic support treatment, and there was still a lack of specific antiviral drug and safe and effective preventive measures. In recent years, many drugs have entered the post-clinical research phase, and some drugs have been on the market. This article reviews the research progress of early antiviral drug and new antiviral drug for the treatment of RSV, as well as the prevention strategies of active and passive immunity of RSV, in order to improve clinicians' understanding of the prevention and treatment strategies of children's RSV.

R985；R978.7

天津市醫(yī)學(xué)重點學(xué)科(專科)建設(shè)項目(TJYXZDXK-040A)